On January 20, 2026, Fraunhofer IWS announced COLDIMPACT, an automated vitrification platform developed with Fraunhofer ITEM and Fraunhofer IBMT under the Prepare preliminary research programme. The platform targets cryopreserved lung sections for pharmaceutical research and replaces manual, case-by-case handling with controlled liquid handling, microsystem-engineered tissue carriers, sensors, and cameras. Its stated project duration is April 2023 to March 2026, with the goal of producing high-quality tissue sections with theoretically unlimited availability and an almost unlimited shelf life.[1][2][5][6][10]
The technical significance is process reproducibility rather than merely low-temperature storage. COLDIMPACT controls media exchanges, rinsing sequences, tissue handling, temperature transitions, and cooling rates while preserving tissue morphology and functional properties. Its modular architecture can be adapted to tissue types, cryoprotectants, and process parameters, creating a possible pathway toward standardized biological inventories that remain usable without continuous access to fresh human donors.[1][2]
The Ark team should track COLDIMPACT validation data after the March 2026 project endpoint, especially post-thaw viability, functional performance, repeatability, cryoprotectant toxicity, storage-duration evidence, and failure rates. Research should assess whether the platform can be redesigned for lunar deployment or terrestrial pre-positioning, with redundant power, autonomous monitoring, contamination control, repairable components, and validated protocols for lung, reproductive, hematopoietic, neural, and organoid tissues.